# KLOW Peptide Side Effects: safety signals for the KLOW peptide blend

> KLOW peptide side effects are component-level and theoretical — no blend safety study exists. The WADA ban, copper load, angiogenesis caution and PK mismatch, cited.

There is no adverse-event profile for the blend. What follows is component-level, cited, and honest about which signals are facts and which are theoretical.

## The short version

When people search KLOW peptide side effects, the honest first answer is that there is no clinical safety profile for the four-peptide blend — it has never been tested in a controlled study. What exists comes from two sources, and they are very different in weight. One is community reports: things people say they felt, with no verified dose and no quality control. The other is real, citable cautions drawn from how the ingredients behave: TB-500 is on the anti-doping banned list, three of the four peptides encourage new blood-vessel growth (a theoretical concern for anyone with cancer), the copper-rich GHK-Cu raises a load question for people who cannot process copper, and the four ingredients clear at such different speeds that the mixture cannot be dosed evenly. This page keeps those two layers clearly apart.

## What are the side effects of the KLOW peptide?

No clinical adverse-event profile exists for the blend [1]. The most-cited community reports (anecdotal, with no verified dose) are injection-site redness or itching, transient fatigue, mild headache, flushing and brief stomach upset — these are field impressions, not measured outcomes, and are listed in full on [what KLOW is studied for](/effects). The cited concerns that carry more weight are regulatory and mechanistic: TB-500's place on the WADA Prohibited List [8][9], a theoretical angiogenesis-and-malignancy caution shared by three of the four components [10][6], and the copper load from the mass-dominant GHK-Cu [4][11].

## The anti-doping fact: TB-500 is prohibited

Athletes and anyone subject to anti-doping testing should treat KLOW as off-limits. TB-500 is the synthetic fragment of thymosin beta-4, which is named on the WADA Prohibited List under S2 (peptide hormones and growth factors), banned at all times in and out of competition [8][9]. Because TB-500 is one of the four components, using the blend implicates anti-doping rules regardless of intent. This is the firmest safety-relevant fact on the page — a regulatory status, not a theoretical extrapolation.

## The theoretical angiogenesis caution

People with an active or recent cancer have a specific reason for caution. Three of the four components — BPC-157, TB-500/thymosin beta-4, and GHK-Cu — are pro-angiogenic, meaning they promote new blood-vessel growth; BPC-157 does so through the VEGFR2-Akt-eNOS pathway [10][6]. Because solid tumors depend on new blood vessels to grow, accelerating that growth is a theoretical concern flagged in the literature. No human study has tested this either way for any component or for the blend, so this is a mechanistic caution, not a demonstrated clinical risk — but it is a real reason for caution in that specific group.

## The copper load and the untested-combination problem

GHK-Cu is the mass-dominant component (about 50 of 80 mg) and each molecule carries a chelated copper(II) ion, so the blend delivers more copper than other peptide stacks of its type [4][11]. For people with copper-handling disorders such as Wilson's disease, repeated copper delivery is a theoretical concern that follows directly from the chemistry, though no clinical study has examined accumulation from GHK-Cu in such individuals. Separately, the combination itself must be treated as untested: every component was studied alone, and the four-peptide mixture has never been tested in any controlled study [1]. A pharmacokinetic mismatch compounds the uncertainty — BPC-157's half-life is under about 30 minutes and the tripeptides clear faster still, so one dose cannot hold all four at matched exposures [7]. People with autoimmune disease or an active infection should also weigh the KPV anti-inflammatory arm carefully, since dampening inflammatory signaling is an unpredictable variable in those settings [3][12].

---

A calm, plain-English reading of the four-peptide KLOW record — each ingredient's studies surfaced gently and the untested blend named as the honest gap it is, with no clinic behind the page and nothing here dosed or sold.